View in EDS

Ligelizumab Immunogenicity and Impact on Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety in Patients With Chronic Spontaneous Urticaria.

Saved in:
Bibliographic Details
Title: Ligelizumab Immunogenicity and Impact on Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety in Patients With Chronic Spontaneous Urticaria.
Authors: Ji Y; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA., Calonder C; Novartis BioMedical Research, Basel, Switzerland., Kirsiläe T; Novartis Pharma AG, Basel, Switzerland., Burciu A; Novartis Pharma AG, Basel, Switzerland., Laurent N; Novartis BioMedical Research, Basel, Switzerland., Hua E; China Novartis Biomedical Research Co. Ltd, Shanghai, China., Severin T; Novartis Pharma AG, Basel, Switzerland., Patekar M; Novartis Pharma AG, Basel, Switzerland., Woessner R; Novartis BioMedical Research, Basel, Switzerland.
Source: Clinical and translational science [Clin Transl Sci] 2026 Jul; Vol. 19 (7), pp. e70661.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III
Journal Info: Publisher: WileyBlackwell Pub Country of Publication: United States NLM ID: 101474067 Publication Model: Print Cited Medium: Internet ISSN: 1752-8062 (Electronic) Linking ISSN: 17528054 NLM ISO Abbreviation: Clin Transl Sci Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 42443720
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Ligelizumab Immunogenicity and Impact on Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety in Patients With Chronic Spontaneous Urticaria.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Ji+Y%22">Ji Y</searchLink>; Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Calonder+C%22">Calonder C</searchLink>; Novartis BioMedical Research, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Kirsiläe+T%22">Kirsiläe T</searchLink>; Novartis Pharma AG, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Burciu+A%22">Burciu A</searchLink>; Novartis Pharma AG, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Laurent+N%22">Laurent N</searchLink>; Novartis BioMedical Research, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Hua+E%22">Hua E</searchLink>; China Novartis Biomedical Research Co. Ltd, Shanghai, China.<br /><searchLink fieldCode="AU" term="%22Severin+T%22">Severin T</searchLink>; Novartis Pharma AG, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Patekar+M%22">Patekar M</searchLink>; Novartis Pharma AG, Basel, Switzerland.<br /><searchLink fieldCode="AU" term="%22Woessner+R%22">Woessner R</searchLink>; Novartis BioMedical Research, Basel, Switzerland.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101474067%22">Clinical and translational science</searchLink> [Clin Transl Sci] 2026 Jul; Vol. 19 (7), pp. e70661.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22WileyBlackwell+Pub%22">WileyBlackwell Pub </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101474067 <i>Publication Model: </i>Print <i>Cited Medium: </i>Internet <i>ISSN: </i>1752-8062 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2217528054%22">17528054 </searchLink><i>NLM ISO Abbreviation: </i>Clin Transl Sci <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42443720
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/cts.70661
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: e70661
    Titles:
      – TitleFull: Ligelizumab Immunogenicity and Impact on Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety in Patients With Chronic Spontaneous Urticaria.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Ji Y
      – PersonEntity:
          Name:
            NameFull: Calonder C
      – PersonEntity:
          Name:
            NameFull: Kirsiläe T
      – PersonEntity:
          Name:
            NameFull: Burciu A
      – PersonEntity:
          Name:
            NameFull: Laurent N
      – PersonEntity:
          Name:
            NameFull: Hua E
      – PersonEntity:
          Name:
            NameFull: Severin T
      – PersonEntity:
          Name:
            NameFull: Patekar M
      – PersonEntity:
          Name:
            NameFull: Woessner R
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: 2026 Jul
              Type: published
              Y: 2026
          Identifiers:
            – Type: issn-electronic
              Value: 1752-8062
          Numbering:
            – Type: volume
              Value: 19
            – Type: issue
              Value: 7
          Titles:
            – TitleFull: Clinical and translational science
              Type: main
ResultId 1